Elevai Labs Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
0.0214
+0.0001 (0.47%)
At close: Nov 20, 2024, 4:00 PM
0.0210
-0.0004 (-1.87%)
Pre-market: Nov 21, 2024, 7:39 AM EST
Elevai Labs Employees
Elevai Labs had 18 employees as of December 31, 2023.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
$135,898
Profits / Employee
-$303,829
Market Cap
1.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TC Biopharm (Holdings) | 41 |
| LogicMark | 27 |
| Tenon Medical | 21 |
| Catheter Precision | 14 |
| Cyclacel Pharmaceuticals | 12 |
| Bluejay Diagnostics | 10 |
| Revelation Biosciences | 9 |
| ZyVersa Therapeutics | 7 |
ELAB News
- 6 days ago - CORRECTION - Elevai Labs Inc. - GlobeNewsWire
- 6 days ago - Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 16 days ago - Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewsWire
- 4 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - GlobeNewsWire
- 4 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - GlobeNewsWire
- 6 weeks ago - Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - GlobeNewsWire
- 6 weeks ago - REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire
- 7 weeks ago - Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations - GlobeNewsWire